A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

Dapagliflozin helped people reduce fat levels in their liver and avoid liver scarring that comes with the condition, which ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...

A new study reveals that dapagliflozin, a common diabetes medication, could significantly improve conditions like metabolic ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra), said accompanying editorial authors Leila Haddad, MD, and Sebastián ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

AstraZeneca (AZ) has announced that a wider range of chronic kidney disease (CKD) patients across England and Wales will be ...

A new international study has found that over 15 million people across the US, UK, Germany, and France are unknowingly living ...

It was only by chance that Anneka Murphy discovered the awful truth. While at work one day, the primary school teacher was ...